---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-112356"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-09-30T20:30:22+00:00"
generated_at: "2026-10-12T14:06:50.164960+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics receives Nasdaq notice for bid price below $1.00, has until March 24, 2027 to regain compliance

## Summary
- Nasdaq notified Outlook Therapeutics on Sept 25, 2026 that its closing bid price was below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- The company has 180 calendar days, until March 24, 2027, to regain compliance, requiring a closing bid price of at least $1.00 for 10 consecutive business days.
- Outlook may qualify for an additional 180-day period and could effect a reverse stock split to cure the deficiency.
- If not cured by the Compliance Date, Nasdaq will notify of delisting; the company may appeal to a hearings panel, but success is not assured.
- CFO Kevin Lundquist signed the Form 8-K dated September 30, 2026.

## SEC filing metadata
- accession: 0001104659-26-112356
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-09-30T20:30:22+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/0001104659-26-112356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926112356/tm2626478d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-112356
- JSON: https://secwatch.observer/filing/0001104659-26-112356.json
- Plain text: https://secwatch.observer/filing/0001104659-26-112356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.